{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:41Z","timestamp":1791338861322,"version":"4.3.1"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220416"],"award-info":[{"award-number":["RP220416"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K12 CA088084"],"award-info":[{"award-number":["K12 CA088084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP200356"],"award-info":[{"award-number":["RP200356"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["L30 CA171000"],"award-info":[{"award-number":["L30 CA171000"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA234406"],"award-info":[{"award-number":["K22 CA234406"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180035"],"award-info":[{"award-number":["RR180035"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors improve survival in patients with mismatch repair deficiency\/microsatellite instability-high (MSI-H) colorectal cancer. The recurrence outcomes following discontinuation of immunotherapy after prolonged disease control have not been definitively reported in large series. Records from patients with advanced MSI-H colorectal cancer from The University of Texas \u2013 MD Anderson Cancer Center who received immunotherapy between 2014 and 2022 and stopped after prolonged clinical benefit were reviewed. Median progression-free and overall survival were estimated. Associations between the event of recurrence and coexisting mutations (KRAS\/NRAS, BRAFV600E), metastatic organ involvement (lung, liver, lymph node, or peritoneum), metastatic timing (synchronous vs. metachronous), prior immunotherapy [anti-PD-(L)1 alone or in combination with anti-CTLA antibodies], etiology of MSI status (sporadic vs. hereditary non-polyposis colorectal cancer), and duration of immunotherapy were assessed. Sixty-four patients with MSI-H colorectal cancer without progression on immunotherapy were reviewed. Of these 48 and 16 received anti-PD(L)1 antibody alone or in combination with anti-CTLA-4 antibody, respectively. Median exposure to immunotherapy was 17.6 months (range, 1.3\u201351.9). After a median follow-up of 22.6 months (range, 0.3\u201371.7) after stopping immunotherapy, 56 of 64 patients (88%) remained without disease progression. Lung metastases were associated with recurrence\/progression (OR, 6.1; P = 0.04), but coexisting mutation, primary tumor sidedness, and immunotherapy were not. These data provide a retrospective, single-institution analysis that showed that most patients with advanced MSI-H colorectal cancer do not recur after treatment cessation, regardless of the reason for stopping treatment or a variety of patient and disease features, supporting an optimistic prognosis of sustained disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Outcomes for patients with MSI-H colorectal cancer stopping immunotherapy after disease control remain unknown. Sixty-four patients with MSI-H colorectal cancer from our institution stopping treatment for sustained benefit or toxicity were retrospectively assessed. After median follow up of 22 months and median immunotherapy exposure of 18 months, 88% patients remained without progression. All patients who recurred or progressed and were rechallenged with immunotherapy have continued to experience disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0340","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T09:03:14Z","timestamp":1702285394000},"page":"2510-2517","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3095-337X","authenticated-orcid":true,"given":"Kristen","family":"Simmons","sequence":"first","affiliation":[{"name":"1Department of Hematology\/Oncology, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-4940","authenticated-orcid":true,"given":"Jane V.","family":"Thomas","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3575-3611","authenticated-orcid":true,"given":"Kaysia","family":"Ludford","sequence":"additional","affiliation":[{"name":"3Department of General Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-8552","authenticated-orcid":true,"given":"Jason A.","family":"Willis","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-1142","authenticated-orcid":true,"given":"Victoria S.","family":"Higbie","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-4173","authenticated-orcid":true,"given":"Kanwal P.S.","family":"Raghav","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-8115","authenticated-orcid":true,"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9744","authenticated-orcid":true,"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-2213","authenticated-orcid":true,"given":"Bryan K.","family":"Kee","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-097X","authenticated-orcid":true,"given":"Christine M.","family":"Parseghian","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-3423","authenticated-orcid":true,"given":"Michael S.","family":"Lee","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-8149","authenticated-orcid":true,"given":"Phat H.","family":"Le","sequence":"additional","affiliation":[{"name":"3Department of General Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9543-6584","authenticated-orcid":true,"given":"Maria P.","family":"Morelli","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-2775","authenticated-orcid":true,"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-213X","authenticated-orcid":true,"given":"Alisha","family":"Bent","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-3761","authenticated-orcid":true,"given":"Eduardo","family":"Vilar","sequence":"additional","affiliation":[{"name":"4Clinical Cancer Prevention, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-1610","authenticated-orcid":true,"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":true,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-135X","authenticated-orcid":true,"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-2252","authenticated-orcid":true,"given":"Van Karlyle","family":"Morris","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, The University of Texas \u2013 MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"2023121114030025600_bib1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"2023121114030025600_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2000.18.11.2193","article-title":"Population-based molecular detection of hereditary nonpolyposis colorectal cancer","volume":"18","author":"Salovaara","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3322\/canjclin.56.4.213","article-title":"Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians","volume":"56","author":"Hendriks","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"2023121114030025600_bib4","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1073\/pnas.95.12.6870","article-title":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","volume":"95","author":"Herman","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023121114030025600_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2023121114030025600_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2015","journal-title":"Genome Biol"},{"key":"2023121114030025600_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.celrep.2016.10.009","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"17","author":"Giannakis","year":"2016","journal-title":"Cell Rep"},{"key":"2023121114030025600_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2023121114030025600_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2023121114030025600_bib10","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121114030025600_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2023121114030025600_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2023121114030025600_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023121114030025600_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"2023121114030025600_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2020.08.009","article-title":"Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest","volume":"139","author":"Moretto","year":"2020","journal-title":"Eur J Cancer"},{"key":"2023121114030025600_bib20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023121114030025600_bib21","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"2023121114030025600_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann Oncol"},{"key":"2023121114030025600_bib23","doi-asserted-by":"crossref","first-page":"e47054","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani","year":"2012","journal-title":"PLoS One"},{"key":"2023121114030025600_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023121114030025600_bib25","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023121114030025600_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/djaa052","article-title":"Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer","volume":"113","author":"Ludford","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2023121114030025600_bib27","doi-asserted-by":"crossref","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023121114030025600_bib28","doi-asserted-by":"crossref","first-page":"e230400","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association between survival and metastatic site in mismatch repair\u2013deficient metastatic colorectal cancer treated with first-line pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2023121114030025600_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CCC.2006.n.036","article-title":"Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab","volume":"6","author":"Yoo","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"2023121114030025600_bib30","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ejca.2006.04.012","article-title":"Towards a pan-European consensus on the treatment of patients with colorectal liver metastases","volume":"42","author":"Van Cutsem","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2510\/3389921\/crc-23-0340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2510\/3389921\/crc-23-0340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T09:03:32Z","timestamp":1702285412000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/12\/2510\/731647\/Sustained-Disease-Control-in-Immune-Checkpoint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,11]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0340","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24787426.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787420.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787423.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787423","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787417.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787414.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787411.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24787408","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6975005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6975005","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]}}}